Seeking Alpha
 

PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP)

- NYSEARCA
  • Wed, Apr. 8, 3:23 PM
    • What's the Market Vector Israel ETF (ISRA +2.9%) doing owning a 12% stake in Perrigo? It turns out Perrigo has a stock listing in Tel Aviv as well, thanks to its 2005 purchase of Agis Industries, then Israel's 2nd-largest drug maker.
    • In fact, Perrigo is the only non-Israeli company in the country's benchmark TA-25 Index.
    • The iShares U.S. Pharma ETF (IHE +2.4%) and the PowerShares Dynamic Pharma ETF (PJP +2.5%) are also on the move thanks to Perrigo.
    • Source: Barron's
    • Previously: Mylan makes $205/share bid for Perrigo; Generic firms rally (April 8)
    | 1 Comment
  • May. 8, 2014, 7:35 AM
    • China intends to end price limits on low-cost drugs after the controls caused quality problems and shortages.
    • China's economic planning body, the National Development & Reform Commission, will lift price caps on 280 drugs provided by Western companies and 250 Chinese patent medicines.
    • Sanofi (SNY) and Pfizer (PFE) said it's too early to ascertain the impact of the new policy. Other companies that could be affected include GlaxoSmithKline (GSK).
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
    | Comment!
  • Apr. 25, 2014, 2:49 PM
    • Much of the high tech equipment hospitals use can be easily hacked and could pose a significant danger to patients according to the head of information security at Essentia Health.
    • Imaging equipment, insulin pumps, defibrillators and refrigerators that store blood and drugs are examples of networked gear that have remote access control features.
    • The devices' software is plagued by common security holes like weak passwords, lack of authentication to access, easy-to-determine default and hard-coded passwords and embedded web servers and administrative interfaces that make it easy to identify and manipulate devices once found on the network.
    • Hospital are apparently just waking up to the potential risks.
    • Last spring, the FDA and DHS issued a notice to the health care industry about problems with hard-coded passwords after researchers found issues in ~300 devices.
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Comment!
  • Apr. 22, 2014, 12:14 PM
    | Comment!
  • Apr. 22, 2014, 11:33 AM
    • The FDA proposes an "Expedited Access PMA" (EAP) process for medical devices that treat or diagnose patients with serious conditions whose medical needs are unmet by current technology. The program features earlier and more interactive participation by agency staff to collaboratively develop a plan for the collection of the scientific and clinical data to support approval. The EAP aims to reduce certain devices' development times in addition to the expected shortened premarket review.
    • Eligible devices must fit the following profile: 1) be intended to treat or diagnose a life-threatening or irreversibly-debilitating disease or condition and 2) represent one of the following: no approved alternative treatment/diagnostic exists or it represents a breakthrough technology that provides a clinically meaningful advantage over existing technology or offers a significant clinically meaningful advantage over currently-available alternatives or the device's availability is in the patient's best interest.
    • The proposed EAP builds on the Expedited Access Program for pharmaceuticals that the FDA launched in 2011.
    • Draft guidance
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Comment!
  • Apr. 17, 2014, 1:30 PM
    • Scientists create patient-specific cell lines from the skin cells of two adult men in a procedure called somatic cell nuclear transfer demonstrating that the technique can work for people of all ages. The embryonic cells are genetically identical to the donor and have profound therapeutic potential.
    • The cloning procedure is difficult, however. Only one in thirty-nine attempts was successful.
    • In therapeutic cloning, a jolt of electricity fuses a grown cell (e.g. skin cell) with an ovum whose DNA has been removed. After ~5 days of dividing and multiplying it develops into a hollow sphere-shaped embryo. The interior cells are pluripotent stem cells which can develop into many different kinds of cells. The goal is to coax them to develop into specialized cells for therapeutic purposes.
    • Complicating the ability to create patient-specific cell lines for millions of people are women's reticence over donating eggs, a sometimes painful process. Widespread donations may not be ultimately necessary since many people have genetically similar immune systems so 100 human embryonic stem cell lines would match over 50% of the U.S. population according to the co-author of the study, Dr. Robert Lanza.
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, PTH, XHE, DRGS, RXD
    | Comment!
  • Apr. 17, 2014, 8:04 AM
    • In a novel cancer study funded with $42M by Cancer Research UK, scientists will test up to 14 different cancer drugs at the same time within one clinical trial. The objective is to identify the most effective treatments for advanced lung cancer by targeting specific rare genetic mutations.
    • The new approach will select a range of drugs for a specific patient instead of designing a study around a specific drug. In a profound change it eliminates randomization, the hallmark of clinical trial design.
    • Some mutations occur on only 1% - 2% of patients so the traditional method of clinical trial design is too expensive, time-consuming and inefficient.
    • AstraZeneca (AZN) will supply up to twelve experimental drugs that will be given to patients who do not show one of twenty-one sets of genetic abnormalities.
    • Pfizer (PFE) will supply its lung cancer drug Xalkori plus the experimental breast cancer drug palbociclib.
    • About 15-20 patients will be involved in the trial. Those drugs that show no benefit will be quickly dropped while those showing efficacy will be fast-tracked into larger-scale testing.
    • Healthcare ETFs: IYH, IBB, XLV, XBI, BIB, VHT, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
    | Comment!
  • Apr. 4, 2014, 1:12 PM
    | 6 Comments
  • Feb. 14, 2014, 11:35 AM
    | 5 Comments
  • Sep. 12, 2013, 10:07 AM
    • U.S. bio-pharmaceutical companies are developing 271 vaccines to prevent and even treat numerous conditions, a report from the Pharmaceutical Research & Manufacturers of America says.
    • The conditions targeted include infectious diseases and various forms of cancer and neurological disorders.
    • In the U.S., 10 infectious diseases have been at least 90% eradicated because of vaccines.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS, XPH, IHE, PJP, PPH, DRGS
    | Comment!
  • May. 6, 2013, 1:36 PM
    Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses.
    | Comment!
  • Apr. 30, 2012, 5:20 AM
    Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees.
    | Comment!
  • Apr. 17, 2012, 1:29 PM
    Express Scripts (ESRX +2.5%) says prescription drug spending fell to 2.7% growth in 2011 - the slowest pace in 18 years - due to the introduction of generic medicines that tempered price increases. The company notes that the average co-payment for consumers fell to $12.02 a prescription from $12.10 a year before.
    | Comment!
  • Apr. 3, 2012, 10:04 AM
    Push comes to shove as pricey life-saving cancer drugs run up against government austerity programs and private payers unwilling to share costs for drugs that run as high as $100K a year. While Big Pharma argues that advanced technology will save money on the development side, companies such as PFE, BMY, RHHBY, and BAYRY.PK run the risk of seeing reduced profits with government-mandated price cuts for their most expensive drugs.
    | 4 Comments
  • Mar. 14, 2012, 2:33 PM
    Downsizing: Only two of the top ten drugmakers increased their promotional spending last year, according to analysis from Cegedim Strategic Data. Overall, global investment on sales and marketing declined 3.4% to $92B.
    | Comment!
  • Jan. 18, 2012, 12:01 PM
    Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil.
    | Comment!
Visit Seeking Alpha's
PJP vs. ETF Alternatives
PJP Description
The PowerShares Dynamic Pharmaceuticals Portfolio (Fund) is based on the Dynamic Pharmaceuticals Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub